- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 20.12. | JUNSHI BIO (01877): LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS | - | HKEx | ||
| 20.12. | JUNSHI BIO (01877): ELECTION OF INDEPENDENT NON-EXECUTIVE DIRECTORS CHANGE IN COMPOSITION OF THE AUDIT COMMITTEE AND THE STRATEGIC COMMITTEE | - | HKEx | ||
| 20.12. | JUNSHI BIO (01877): ARTICLES OF ASSOCIATION | - | HKEx | ||
| 20.12. | JUNSHI BIO (01877): POLL RESULTS OF THE 2024 FIRST EXTRAORDINARY GENERAL MEETING | - | HKEx | ||
| 29.11. | JUNSHI BIO (01877): FORM OF PROXY FOR THE 2024 FIRST EXTRAORDINARY GENERAL MEETING TO BE HELD ON FRIDAY, 20 DECEMBER 2024 | 2 | HKEx | ||
| SHANGHAI JUNSHI BIOSCIENCES Aktie jetzt für 0€ handeln | |||||
| 29.11. | JUNSHI BIO (01877): NOTICE OF THE 2024 FIRST EXTRAORDINARY GENERAL MEETING | - | HKEx | ||
| 29.11. | JUNSHI BIO (01877): (1) UTILIZATION OF REMAINING OVER-SUBSCRIPTION PROCEEDS FOR PERMANENT REPLENISHMENT OF LIQUIDITY (2) ELECTION OF INDEPENDENT NON-EXECUTIVE ... | 2 | HKEx | ||
| 29.11. | JUNSHI BIO (01877): PROPOSED ELECTION AND RESIGNATION OF INDEPENDENT NON-EXECUTIVE DIRECTORS | 3 | HKEx | ||
| 29.11. | JUNSHI BIO (01877): CLOSURE OF REGISTER OF MEMBERS OF H SHARES | 1 | HKEx | ||
| 29.11. | JUNSHI BIO (01877): (1) CHANGE OF REGISTERED ADDRESS IN THE PRC, PROPOSED AMENDMENTS TO THE ARTICLES OF ASSOCIATION AND THE INDUSTRIAL AND COMMERCIAL ... | 1 | HKEx | ||
| 29.11. | JUNSHI BIO (01877): OVERSEAS REGULATORY ANNOUNCEMENT | 1 | HKEx | ||
| 28.11. | JUNSHI BIO (01877): VOLUNTARY ANNOUNCEMENT - NEW INDICATIONS OF TUOYI HAVE BEEN INCLUDED IN THE NATIONAL REIMBURSEMENT DRUG LIST | - | HKEx | ||
| 19.11. | JUNSHI BIO (01877): VOLUNTARY ANNOUNCEMENT - ENTERING INTO OF THE LICENSE AGREEMENT | 2 | HKEx | ||
| 16.11. | Junshi Biosciences Announces UK MHRA Approval for Marketing of Toripalimab | 472 | GlobeNewswire (Europe) | SHANGHAI, Nov. 16, 2024 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the... ► Artikel lesen | |
| 15.11. | JUNSHI BIO (01877): VOLUNTARY ANNOUNCEMENT - APPROVAL BY THE MHRA FOR MARKETING OF TORIPALIMAB | - | HKEx | ||
| 12.11. | JUNSHI BIO (01877): OVERSEAS REGULATORY ANNOUNCEMENT - SHANGHAI JUNSHI BIOSCIENCES CO., LTD.* ANNOUNCEMENT ON THE COMPLETION OF THE PLAN FOR THE REDUCTION ... | - | HKEx | ||
| 29.10. | JUNSHI BIO (01877): OVERSEAS REGULATORY ANNOUNCEMENT - SHANGHAI JUNSHI BIOSCIENCES CO., LTD.* INDICATIVE ANNOUNCEMENT ON THE CHANGES IN EQUITY OF THE ... | 11 | HKEx | ||
| 29.10. | JUNSHI BIO (01877): OVERSEAS REGULATORY ANNOUNCEMENT - SHANGHAI JUNSHI BIOSCIENCES CO., LTD.* ANNOUNCEMENT ON THE CONVENING OF THE 2024 THIRD QUARTERLY ... | 1 | HKEx | ||
| 29.10. | JUNSHI BIO (01877): OVERSEAS REGULATORY ANNOUNCEMENT - SHANGHAI JUNSHI BIOSCIENCES CO., LTD.* ANNOUNCEMENT ON CHANGING THE IMPLEMENTATION ENTITY FOR INVESTMENT ... | 1 | HKEx | ||
| 29.10. | JUNSHI BIO (01877): OVERSEAS REGULATORY ANNOUNCEMENT - SHANGHAI JUNSHI BIOSCIENCES CO., LTD.* ANNOUNCEMENT ON UTILIZING THE REMAINING SURPLUS PROCEEDS ... | - | HKEx |
Seite:
1 2 3 Weiter >>
60 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| CG ONCOLOGY | 30,040 | +3,19 % | CG Oncology Inc.: CG Oncology Reports Second Quarter 2024 Financial Results and Provides Business Updates | - Final positive safety and efficacy findings from CORE-001 study of Cretostimogene Grenadenorepvec in combination with Pembrolizumab in BCG-Unresponsive NMIBC simultaneously published online by Nature... ► Artikel lesen | |
| QUANTUM-SI | 3,575 | +66,28 % | Pre-market Movers: Intrusion, SES AI, Solid Power, Quantum-Si, Rail Vision | OTTAWA (dpa-AFX) - The following are some of the stocks making big moves in Friday's pre-market trading (as of 07.55 A.M. ET).In the Green Intrusion Inc. (INTZ) is up over 380% at $2.16.
SES... ► Artikel lesen | |
| QIAGEN | 43,310 | +0,69 % | Biotech Report: Qiagen und Evotec leichter | (shareribs.com) Frankfurt / New York 20.12.2024 - Zum Ende der letzten Handelswoche des Jahres stehen die Biotechwerte unter Druck. Im deutschen Handel geht es für Evotec und Qiagen abwärts.Der DAX... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 7,390 | -3,52 % | Recursion Pharmaceuticals Reports Grant of Inducement Awards as Permitted by the Nasdaq Listing Rules | Salt Lake City, Utah, Dec. 20, 2024 (GLOBE NEWSWIRE) -- Recursion Pharmaceuticals, Inc. ("Recursion") (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug... ► Artikel lesen | |
| TEMPUS AI | 35,120 | -0,48 % | Cathie Woods ARK kauft AMD und TEMPUS AI, verkauft ARCHER AVIATION | ||
| NUVALENT | 80,30 | -2,14 % | Nuvalent-Direktor Shair verkauft Aktien im Wert von 167.565 US-Dollar | ||
| EVOTEC | 8,535 | +1,49 % | INDEX-MONITOR: Evotec und Auto1 im MDax - Befesa und Stabilus raus | ZUG (dpa-AFX) - Der Pharma-Wirkstoffforscher Evotec und der Online-Autohändler Auto1 kehren in den Index der mittelgroßen Börsenwerte, den MDax, zurück. Im Gegenzug steigen der Industrie-Recycler Befesa... ► Artikel lesen | |
| TARSUS PHARMACEUTICALS | 55,00 | +1,20 % | How Tarsus Pharmaceuticals' Unique Inspiration Is Driving A Triple-Digit Run | ||
| DYNE THERAPEUTICS | 23,720 | -3,06 % | Dyne Therapeutics Reports Positive Data From Phase 1/2 DELIVER Trial Of DYNE-251 In DMD | WASHINGTON (dpa-AFX) - Tuesday, Dyne Therapeutics, Inc. (DYN) revealed new clinical findings from its Phase 1/2 DELIVER trial of DYNE-251 for patients with Duchenne muscular dystrophy also known... ► Artikel lesen | |
| BIONTECH | 109,40 | -0,18 % | Biontech und Pfizer zahlen für Vergleich in USA | MAINZ (dpa-AFX) - Der Impfstoffhersteller Biontech hat in den USA im Streit um Lizenzgebühren millionenschwere Vergleiche geschlossen. Insgesamt umgerechnet 1,2 Milliarden Euro werden das Unternehmen... ► Artikel lesen | |
| ARS PHARMACEUTICALS | 10,790 | -3,23 % | ARS Pharmaceuticals, Inc.: ARS Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Updates | Commercial launch of neffy® (epinephrine nasal spray) underway in the United StatesSupplemental NDA for neffy®1mg dose granted priority review by FDA; PDUFA target date set for March 6, 2025Exclusive... ► Artikel lesen | |
| CELCUITY | 13,840 | +5,81 % | Celcuity (NASDAQ:CELC) Trading Up 3.8% - Here's Why | ||
| HUMACYTE | 5,500 | +3,97 % | Humacyte (NASDAQ:HUMA) Shares Up 6% - Here's What Happened | ||
| RELAY THERAPEUTICS | 4,360 | -2,02 % | Relay Therapeutics, Inc.: Relay Therapeutics Announces Updated Interim Data for RLY-2608 + Fulvestrant Demonstrating Continued Maturation of Clinically Meaningful Progression Free Survival | New interim data show 11.4-month median PFS in 2L patients with PI3Ka-mutated, HR+/HER2- metastatic breast cancer at RP2D 39% confirmed ORR across all patients & 67% in patients with kinase mutations... ► Artikel lesen | |
| CANDEL THERAPEUTICS | 8,870 | -3,27 % | Pre-market Movers: Loop Industries, Repare Therapeutics, Candel Therapeutics, Inovio Pharmaceuticals, iSpecimen | OTTAWA (dpa-AFX) - The following are some of the stocks making big moves in Friday's pre-market trading (as of 07.35 A.M. ET).In the Green Loop Industries, Inc. (LOOP) is up over 56% at $1.93.
iSpecimen... ► Artikel lesen |
SHANGHAI JUNSHI BIOSCIENCES CO LTD gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 1,410 Euro und damit 0,00 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu SHANGHAI JUNSHI BIOSCIENCES CO LTD finden Sie auf Wallstreet Online.
